These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16940442)

  • 1. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.
    Page ST; Amory JK; Anawalt BD; Irwig MS; Brockenbrough AT; Matsumoto AM; Bremner WJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4374-80. PubMed ID: 16940442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen.
    Amory JK; Page ST; Anawalt BD; Matsumoto AM; Bremner WJ
    Contraception; 2007 Mar; 75(3):218-23. PubMed ID: 17303493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI; O'Donnell L; Stanton PG; Balourdos G; Frydenberg M; de Kretser DM; Robertson DM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
    Bremner WJ; Bagatell CJ; Steiner RA
    J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contraceptive efficacy of a depot progestin and androgen combination in men.
    Turner L; Conway AJ; Jimenez M; Liu PY; Forbes E; McLachlan RI; Handelsman DJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4659-67. PubMed ID: 14557437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.
    Mahabadi V; Amory JK; Swerdloff RS; Bremner WJ; Page ST; Sitruk-Ware R; Christensen PD; Kumar N; Tsong YY; Blithe D; Wang C
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2313-20. PubMed ID: 19366848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men.
    Gu YQ; Tong JS; Ma DZ; Wang XH; Yuan D; Tang WH; Bremner WJ
    J Clin Endocrinol Metab; 2004 May; 89(5):2254-62. PubMed ID: 15126550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment.
    Page ST; Kalhorn TF; Bremner WJ; Anawalt BD; Matsumoto AM; Amory JK
    J Androl; 2007; 28(5):734-41. PubMed ID: 17494097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone.
    Behre HM; Kliesch S; Lemcke B; von Eckardstein S; Nieschlag E
    Hum Reprod; 2001 Dec; 16(12):2570-7. PubMed ID: 11726576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
    Pangkahila W
    Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.